Interpace Biosciences Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Interpace Biosciences Inc has an operating margin of 17.3%, meaning the company retains $17 of operating profit per $100 of revenue. This strong profitability earns a score of 86/100, reflecting efficient cost management and pricing power. This is up from 9.9% the prior year.
Interpace Biosciences Inc's revenue surged 17.2% year-over-year to $46.9M, reflecting rapid business expansion. This strong growth earns a score of 78/100.
Interpace Biosciences Inc's current ratio of 1.11 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 24/100, which could limit financial flexibility.
Interpace Biosciences Inc has a free cash flow margin of 8.0%, earning a moderate score of 40/100. The company generates positive cash flow after capital investments, but with room for improvement.
Interpace Biosciences Inc scores -17.07, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.6M) relative to total liabilities ($17.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Interpace Biosciences Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Interpace Biosciences Inc generates $0.69 in operating cash flow ($4.6M OCF vs $6.7M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
This page shows Interpace Biosciences Inc (IDXG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Interpace Biosciences Inc generated $46.9M in revenue in fiscal year 2024. This represents an increase of 17.2% from the prior year.
Interpace Biosciences Inc's EBITDA was $8.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.8% from the prior year.
Interpace Biosciences Inc generated $3.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 13.6% from the prior year.
Interpace Biosciences Inc reported $6.7M in net income in fiscal year 2024. This represents an increase of 243.0% from the prior year.
Interpace Biosciences Inc earned $0.40 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 11.1% from the prior year.
Interpace Biosciences Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.
Interpace Biosciences Inc had 4M shares outstanding in fiscal year 2024. This represents an increase of 1.3% from the prior year.
Interpace Biosciences Inc's gross margin was 63.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
Interpace Biosciences Inc's operating margin was 17.3% in fiscal year 2024, reflecting core business profitability. This is up 7.4 percentage points from the prior year.
Interpace Biosciences Inc's net profit margin was 14.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 9.4 percentage points from the prior year.
Interpace Biosciences Inc invested $676K in research and development in fiscal year 2024. This represents an increase of 6.3% from the prior year.
Interpace Biosciences Inc invested $876K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 86.4% from the prior year.
IDXG Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M-5.2% | $9.2M-19.8% | $11.5M-7.2% | $12.4M+3.1% | $12.0M+18.3% | $10.2M+0.4% | $10.1M+10.1% | $9.2M |
| Cost of Revenue | $3.3M-16.2% | $4.0M-4.6% | $4.1M-8.0% | $4.5M+6.4% | $4.2M+9.5% | $3.9M+1.3% | $3.8M-0.1% | $3.8M |
| Gross Profit | $5.4M+3.1% | $5.3M-28.4% | $7.4M-6.8% | $7.9M+1.3% | $7.8M+23.7% | $6.3M0.0% | $6.3M+17.3% | $5.4M |
| R&D Expenses | $150K-13.3% | $173K-2.3% | $177K-8.8% | $194K+32.9% | $146K+6.6% | $137K-9.9% | $152K+2.0% | $149K |
| SG&A Expenses | $2.1M-22.7% | $2.7M+4.4% | $2.5M-0.7% | $2.6M+19.9% | $2.1M-4.4% | $2.2M+21.0% | $1.9M-12.9% | $2.1M |
| Operating Income | $1.1M+344.7% | -$468K-125.6% | $1.8M-11.3% | $2.1M-21.7% | $2.6M+136.3% | $1.1M-25.2% | $1.5M+261.7% | $412K |
| Interest Expense | $30K-38.8% | $49K-37.2% | $78K-44.7% | $141K-19.9% | $176K-10.7% | $197K+1085.0% | -$20K+23.1% | -$26K |
| Income Tax | -$11K | N/A | $18K+325.0% | -$8K-300.0% | $4K0.0% | $4K-20.0% | $5K+25.0% | $4K |
| Net Income | $911K+242.3% | -$640K-138.9% | $1.6M-12.4% | $1.9M-22.8% | $2.4M+244.2% | $708K-33.6% | $1.1M+673.7% | -$186K |
| EPS (Diluted) | $0.03+121.4% | $-0.14-333.3% | $0.06+108.7% | $-0.69-225.5% | $0.55+243.8% | $0.16-33.3% | $0.24+700.0% | $-0.04 |
IDXG Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.0M-2.4% | $12.3M-14.9% | $14.5M-2.0% | $14.8M+14.0% | $13.0M+6.8% | $12.1M-7.4% | $13.1M-8.0% | $14.3M |
| Current Assets | $9.1M-3.9% | $9.5M-18.4% | $11.7M-1.0% | $11.8M+23.9% | $9.5M+0.9% | $9.4M-9.6% | $10.4M-8.9% | $11.4M |
| Cash & Equivalents | $1.4M+183.5% | $502K-58.0% | $1.2M-18.1% | $1.5M+192.2% | $500K-82.2% | $2.8M-19.6% | $3.5M-30.5% | $5.0M |
| Inventory | $1.1M+13.5% | $973K-19.5% | $1.2M-0.2% | $1.2M-1.6% | $1.2M+6.7% | $1.2M-5.9% | $1.2M+12.3% | $1.1M |
| Accounts Receivable | $6.0M-17.5% | $7.2M-17.5% | $8.8M+2.6% | $8.5M+37.7% | $6.2M+24.0% | $5.0M-1.4% | $5.1M+5.1% | $4.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $12.3M-9.0% | $13.5M-10.1% | $15.1M-11.4% | $17.0M-73.9% | $65.3M-2.5% | $66.9M-2.5% | $68.7M-3.3% | $71.0M |
| Current Liabilities | $5.9M-16.8% | $7.1M-17.6% | $8.7M-18.2% | $10.6M+49.5% | $7.1M-43.7% | $12.6M+10.2% | $11.4M-7.2% | $12.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$298K+75.4% | -$1.2M-108.4% | -$582K+73.7% | -$2.2M+95.8% | -$52.3M+4.5% | -$54.8M+1.4% | -$55.5M+2.1% | -$56.7M |
| Retained Earnings | -$233.5M+0.4% | -$234.4M-0.3% | -$233.7M+0.7% | -$235.4M+1.5% | -$238.9M+1.0% | -$241.4M+0.3% | -$242.1M+2.8% | -$249.1M |
IDXG Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.9M+272.7% | $520K-57.9% | $1.2M+4.3% | $1.2M-15.7% | $1.4M+2520.7% | -$58K-105.1% | $1.1M+3.2% | $1.1M |
| Capital Expenditures | $117K | N/A | N/A | $129K-34.5% | $197K+603.6% | $28K-80.3% | $142K-6.6% | $152K |
| Free Cash Flow | $1.8M | N/A | N/A | $1.1M-12.6% | $1.2M+1503.5% | -$86K-108.6% | $998K+4.7% | $953K |
| Investing Cash Flow | -$117K | N/A | N/A | -$129K+34.5% | -$197K-603.6% | -$28K+80.3% | -$142K-140.8% | $348K |
| Financing Cash Flow | -$900K+11.2% | -$1.0M+32.5% | -$1.5M+12.1% | -$1.7M+14.6% | -$2.0M-233.3% | -$600K+76.3% | -$2.5M-68.8% | -$1.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IDXG Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.1%+5.0pp | 57.1%-6.9pp | 64.0%+0.3pp | 63.7%-1.1pp | 64.8%+2.8pp | 62.0%-0.3pp | 62.3%+3.8pp | 58.5% |
| Operating Margin | 13.1%+18.1pp | -5.1%-20.9pp | 15.9%-0.7pp | 16.6%-5.2pp | 21.9%+10.9pp | 10.9%-3.7pp | 14.7%+10.2pp | 4.5% |
| Net Margin | 10.4%+17.3pp | -6.9%-21.2pp | 14.3%-0.9pp | 15.2%-5.1pp | 20.2%+13.3pp | 7.0%-3.6pp | 10.5%+12.6pp | -2.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 7.6%+12.8pp | -5.2%-16.6pp | 11.4%-1.4pp | 12.7%-6.1pp | 18.8%+13.0pp | 5.8%-2.3pp | 8.1%+9.4pp | -1.3% |
| Current Ratio | 1.54+0.2 | 1.33-0.0 | 1.34+0.2 | 1.11-0.2 | 1.34+0.6 | 0.75-0.2 | 0.91-0.0 | 0.93 |
| Debt-to-Equity | -41.39-30.2 | -11.17+14.7 | -25.90-18.2 | -7.67-6.4 | -1.25-0.0 | -1.22+0.0 | -1.24+0.0 | -1.25 |
| FCF Margin | 20.8% | N/A | N/A | 8.5%-1.5pp | 10.0%+10.9pp | -0.8%-10.7pp | 9.8%-0.5pp | 10.4% |
Note: Shareholder equity is negative (-$2.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Interpace Biosciences Inc's annual revenue?
Interpace Biosciences Inc (IDXG) reported $46.9M in total revenue for fiscal year 2024. This represents a 17.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Interpace Biosciences Inc's revenue growing?
Interpace Biosciences Inc (IDXG) revenue grew by 17.2% year-over-year, from $40.0M to $46.9M in fiscal year 2024.
Is Interpace Biosciences Inc profitable?
Yes, Interpace Biosciences Inc (IDXG) reported a net income of $6.7M in fiscal year 2024, with a net profit margin of 14.3%.
What is Interpace Biosciences Inc's earnings per share (EPS)?
Interpace Biosciences Inc (IDXG) reported diluted earnings per share of $0.40 for fiscal year 2024. This represents a -11.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Interpace Biosciences Inc's EBITDA?
Interpace Biosciences Inc (IDXG) had EBITDA of $8.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Interpace Biosciences Inc's gross margin?
Interpace Biosciences Inc (IDXG) had a gross margin of 63.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Interpace Biosciences Inc's operating margin?
Interpace Biosciences Inc (IDXG) had an operating margin of 17.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Interpace Biosciences Inc's net profit margin?
Interpace Biosciences Inc (IDXG) had a net profit margin of 14.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Interpace Biosciences Inc's free cash flow?
Interpace Biosciences Inc (IDXG) generated $3.8M in free cash flow during fiscal year 2024. This represents a 13.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Interpace Biosciences Inc's operating cash flow?
Interpace Biosciences Inc (IDXG) generated $4.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Interpace Biosciences Inc's total assets?
Interpace Biosciences Inc (IDXG) had $14.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Interpace Biosciences Inc's capital expenditures?
Interpace Biosciences Inc (IDXG) invested $876K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Interpace Biosciences Inc spend on research and development?
Interpace Biosciences Inc (IDXG) invested $676K in research and development during fiscal year 2024.
How many shares does Interpace Biosciences Inc have outstanding?
Interpace Biosciences Inc (IDXG) had 4M shares outstanding as of fiscal year 2024.
What is Interpace Biosciences Inc's current ratio?
Interpace Biosciences Inc (IDXG) had a current ratio of 1.11 as of fiscal year 2024, which is considered adequate.
What is Interpace Biosciences Inc's debt-to-equity ratio?
Interpace Biosciences Inc (IDXG) had a debt-to-equity ratio of -7.67 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Interpace Biosciences Inc's return on assets (ROA)?
Interpace Biosciences Inc (IDXG) had a return on assets of 45.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Interpace Biosciences Inc's debt-to-equity ratio negative or unusual?
Interpace Biosciences Inc (IDXG) has negative shareholder equity of -$2.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Interpace Biosciences Inc's Altman Z-Score?
Interpace Biosciences Inc (IDXG) has an Altman Z-Score of -17.07, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Interpace Biosciences Inc's Piotroski F-Score?
Interpace Biosciences Inc (IDXG) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Interpace Biosciences Inc's earnings high quality?
Interpace Biosciences Inc (IDXG) has an earnings quality ratio of 0.69x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Interpace Biosciences Inc?
Interpace Biosciences Inc (IDXG) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.